share_log

Laidlaw & Co. Initiates Coverage On Evofem Biosciences with Buy Rating, Announces Price Target of $3.5

Laidlaw & Co. Initiates Coverage On Evofem Biosciences with Buy Rating, Announces Price Target of $3.5

Laidlaw & Co.以买入评级启动对Evofem Biosciences的报道,宣布目标股价为3.5美元
Benzinga Real-time News ·  2022/06/02 09:30

Laidlaw & Co. analyst Yale Jen initiates coverage on Evofem Biosciences (NASDAQ:EVFM) with a Buy rating and announces Price Target of $3.5.

Laidlaw & Co. 分析师耶鲁·詹开始对Evofem Biosciences(纳斯达克股票代码:EVFM)进行报道,评级为买入,并宣布目标股价为3.5美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发